Reldesemtiv

Drug identity checked against registry records

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031)NCT05442775CytokineticsPhase 3Terminated2023-06-07Actual
A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)NCT04944784CytokineticsPhase 3Terminated2023-07-18Actual

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.